Welcome to the PROGEN Blog
Dive into the fascinating world of gene therapy, meet our dedicated PROGEN team, and more.
Science in Action
Meet Head of Research and Development Klaus-Ingmar Pfrepper and find out about his team’s recent discovery of a new AAV antibody.
Overcoming Liver Accumulation: Extrahepatic Targeting Strategies for Lipid Nanoparticles (LNPs)
New targeting strategies are showing how the accumulation of lipid nanoparticles (LNPs) in the liver can be reduced.
Beyond the Virus: How Non-Viral Vectors Are Changing Gene Therapy
Efficient gene delivery is a key challenge in gene therapy. While viral vectors are widely used, lipid nanoparticles (LNPs) are emerging as promising non-viral alternatives.
Five Challenges Of Applying Lipid Nanoparticles As Delivery Tools For Therapeutic Agents
As effective as these delivery vehicles are, they come with their own set of difficulties.
Maximizing Efficiency
Getting a transgene to be expressed inside the target cell is the name of the game.
Bringing New Products to Market
Meet Silja, she is one of our Product Managers here at @PROGEN who is passionate about making sure the team bring you the right tools at the right time to help you go a step further in your AAV gene therapy projects.
Serving Customers’ Needs
Meet PROGEN’s Business Development Manager Jesse Kay and learn more about why it's important to solve customers' problems.
The Road To Even Safer AAV Gene Therapies
Although AAVs are among the safest gene therapy vectors, they do pose a few risks that can still be reduced.
Comparability Amid Change
When manufacturing changes bring challenges, standard reference materials can save the day.
Helping people become healthy
Meet PROGEN’s co-CEO Maik Lander and learn more about the importance of meeting customers' needs.
Five Reasons to Choose Adeno-associated Viruses for Gene Therapy
These small but mighty DNA delivery vehicles are revolutionizing medicine.
Introducing Recombinant Adeno-associated Viruses (rAAV)
Modifying AAVs makes them more efficient and better at targeting specific tissues.
Supporting the gene therapy community
Meet Katja Betts, co-CEO of PROGEN and find out why supporting the gene therapy community in developing new therapies is her everyday motivation.
